Yunhui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunhui Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Mingjun Yu
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China; Gamma Knife Center, Shengjing Hospital of China Medical University, Shenyang, China; Key Laboratory of Neuro-oncology in Liaoning Province, Shenyang 110004, People's Republic of China
2 shared publicationsShijia Yu
Department of Neurology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China
2 shared publicationsBolong Yi
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China; Key Laboratory of Neuro-oncology in Liaoning Province, Shenyang 110004, People's Republic of China
1 shared publicationDuo Chen
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China
1 shared publicationHai Yu
Department of Neurosurgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China
1 shared publicationWen Zhou
Department of Pain Management, Dalian Municipal Central Hospital, Dalian 116033, People's Republic of China
1 shared publication
Latest Publications
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt A) , 108293
HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt A) , 108293
HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma
- 20 July 2018
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 65 (4) , 411-419
Over-Expressed FEZF1 Predicts a Poor Prognosis in Glioma and Promotes Glioma Cell Malignant Biological Properties by Regulating Akt-ERK Pathway
FEZ family zinc finger 1 (FEZF1) is an essential transcription factor during olfactory development. In gastrointestinal tumors, FEZF1 plays an oncogenic role through DNA demethylation. However, the role of FEZF1 in the prognosis of human glioma prognosis remains unclear. In this research, we discovered that FEZF1 was significantly increased in glioma tissues in contrast to normal brain tissues (NBTs; P < 0.05). Moreover, the expression of FEZF1 showed a significant correlation with Eastern Cooperative Oncology Group performance status, World Health Organization grade, isocitrate dehydrogenase 1 mutation, over-expression of glial fibrillary acidic protein and 1p19q co-deletion. Furthermore, a high level of FEZF1 in patients with glioma acted as an independent biomarker to predict reduced survival (P = 0.026). In an in vitro experiment, FEZF1 can promote the proliferation, migration, and invasion of glioma cells and inhibit cell apoptosis by activating Akt-ERK pathway. All these findings suggest that FEZF1 acts as a key oncogene and predicts a poor prognosis in glioma.
- 20 July 2018
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 65 (4) , 411-419
Over-Expressed FEZF1 Predicts a Poor Prognosis in Glioma and Promotes Glioma Cell Malignant Biological Properties by Regulating Akt-ERK Pathway
FEZ family zinc finger 1 (FEZF1) is an essential transcription factor during olfactory development. In gastrointestinal tumors, FEZF1 plays an oncogenic role through DNA demethylation. However, the role of FEZF1 in the prognosis of human glioma prognosis remains unclear. In this research, we discovered that FEZF1 was significantly increased in glioma tissues in contrast to normal brain tissues (NBTs; P < 0.05). Moreover, the expression of FEZF1 showed a significant correlation with Eastern Cooperative Oncology Group performance status, World Health Organization grade, isocitrate dehydrogenase 1 mutation, over-expression of glial fibrillary acidic protein and 1p19q co-deletion. Furthermore, a high level of FEZF1 in patients with glioma acted as an independent biomarker to predict reduced survival (P = 0.026). In an in vitro experiment, FEZF1 can promote the proliferation, migration, and invasion of glioma cells and inhibit cell apoptosis by activating Akt-ERK pathway. All these findings suggest that FEZF1 acts as a key oncogene and predicts a poor prognosis in glioma.